ClinicalTrials.gg
Status unknownNCT05559242Updated Sep 29, 2022

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

A Phase 1 interventional study of Anlotinib Hydrochloride Capsule in Liver Dysfunction, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-29.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Liver Diseases with a site in China — 19 open to participants now, 21 under way, 1 of them phase 3. Liver Diseases · China.

Planned enrollment
35th of 41
30 · median 90
Started
2022
with 7 others
Phase 1
4 of 64
none open now
Registered
46th of 64
by date

Among the 64 studies in Liver Diseases with a site in China, this one is the 35th largest by planned enrollment of the 41 interventional ones that give a count, is one of 8 that started in 2022, is one of 4 in phase 1, and was the 46th registered.

Liver Diseases

824 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

19 of the 64 studies in Liver Diseases with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Liver Diseases with a site in China, or all of them as a file.
02

Study summary

To evaluate the pharmacokinetic difference of anlotinib hydrochloride capsule between mild/moderate liver dysfunction subjects and healthy subjects, and to provide basis for formulating the clinical drug regimen for patients with liver dysfunction.

03

Conditions studied

  • Liver Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Criteria 1 to 4 are applicable to all subjects.

    1. The subjects volunteered to participate in the study, signed the , and had good compliance;
    2. Age: 18-75 years old (including both end values) (the healthy subject group and the liver dysfunction group are age matched, the mean is ± 10 years); Both male and female (healthy subjects group and liver dysfunction group were matched by gender, mean ± 1 case);
    3. (BMI) ≥ 18 and ≤ 30 kg / m2, and male weight ≥ 50 kg or female weight ≥ 45 kg (weight matching between healthy subjects and liver dysfunction group, mean ± 10%);
    4. Female subjects of childbearing age should agree to use measures (such as IUDs, contraceptives or condoms) during the study and within 6 months after the end of the study; Serum pregnancy test was negative within 7 days before study enrollment, and must be a non lactating subject; Male subjects should agree to use contraceptives during the study period and within 6 months after the end of the study period;
  • Criteria 5 to 8 are applicable to subjects with liver dysfunction. 5. For the subjects with liver dysfunction, they are diagnosed as chronic (≥ 6 months) stable liver function impairment through past medical history, physical examination, serological indicators (such as albumin, , glutamic pyruvic transaminase, glutamic oxaloacetic transaminase, , etc.), liver or imaging (such as computed tomography, magnetic resonance imaging, ultrasound, laparoscopy, etc.); 6. Subjects with liver dysfunction caused by previous primary liver diseases and assessed as grade A / mild (5-6 points) or grade B / moderate (7-9 points) according to grading score (albumin was not used within 14 days); 7. The main organs have good functions and meet the following standards: The blood routine examination shall meet the following standards (no blood transfusion or correction with hematopoietic stimulator drugs within 7 days before screening): (Hgb) ≥ 90g / L; Neutrophil absolute value (neut) ≥ 1.5 × 109/L; Biochemical examination shall meet the following standards: serum creatinine (CR) ≤ 1.5 × or rate (CCR) ≥ 60ml / min; Liver function test shall meet the following standards: alanine transferase () and aspartate transferase (AST) ≤ 5 × ULN; Coagulation function test shall meet the following standards: prothrombin time (PT) extension ≤ 6S, prothrombin activity (PTA) ≥ 40%; Cardiac color Doppler evaluation: (LVEF) ≥ 50%; 8. No drugs affecting were used within 2 weeks before the study;
  • Criteria 9, 10 are applicable to healthy subjects. 9. Main organ function is good, laboratory examination (blood routine, blood biochemistry, coagulation function, etc.), cardiac color ultrasound, 12 lead , abdominal B-ultrasound and other examinations are normal or abnormal, but they are judged by the investigator to be of no clinical significance; 10. Those who did not use any prescription drugs, over-the-counter drugs, Chinese herbal medicines or food supplements within 2 weeks before the study medication;

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria 1 to 15 are applicable to all subjects.

    1. Allergic constitution, including severe drug allergy or drug allergy history; Those who are known to be allergic to anlotinib hydrochloride capsules or their ;
    2. Those who lost blood or donated blood ≥ 450 ml or received blood transfusion within one month before screening; Or having taken any clinical trial drug;
    3. Alcohol breath test is positive or there is a history of alcoholism within 2 weeks before screening (drinking 14 units of alcohol per week: 1 unit = 360ml of beer or 45ml of spirits with 40% alcohol or 150ml of wine); Those who cannot abstain from smoking and drinking during the test;
    4. Those with serious infection, trauma, gastrointestinal surgery or other major surgical operations within 4 weeks before screening;
    5. There are many factors that affect oral administration and drug absorption (such as inability to swallow, gastrointestinal tract resection, ulcerative colitis, symptomatic / inflammatory bowel disease, chronic diarrhea, intestinal obstruction and other digestive tract diseases);
    6. Those who have taken in special diet (such as grapefruit juice / grapefruit juice, methyl xanthine rich coffee, tea, cola, chocolate, energy drinks, etc.) or have taken strenuous exercise or other factors affecting drug absorption, distribution, metabolism, excretion, etc. within 2 days before the study medication;
    7. Those with a history of drug abuse or positive drug screening;
    8. Those who have taken the study drug or participated in clinical trials of other drugs and taken the study drug within one month before screening;
    9. Female subjects who are breastfeeding or whose serum pregnancy results are positive during the screening period;
    10. Have a history of malignant tumor in the past 5 years (except for cured skin basal cell carcinoma and cervical carcinoma in situ);
    11. antibody positive;
    12. There are any serious and / or uncontrollable diseases, including:

      1. blood pressure control is not ideal (systolic blood pressure ≥ 150mmhg or diastolic blood pressure ≥ 100 mmHg);
      2. Have grade ≥ 2 myocardial ischemia or myocardial infarction, arrhythmia (including ≥ 480ms) and grade ≥ 2 congestive heart failure;
      3. Arterial / venous thrombosis events occurred within 6 months, such as cerebrovascular accidents (including , cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;
    13. There are other serious physical or mental diseases, or the history and / or abnormal clinical laboratory tests that the investigator considers may affect the test results, including but not limited to the history of circulatory system, endocrine system, nervous system, digestive system, urinary system or blood, immune, mental and metabolic diseases (excluding the primary liver diseases of patients with liver dysfunction);
    14. There is a history of vaccination within 2 weeks before screening or live attenuated vaccine vaccination is planned during the trial;
    15. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the study, or subjects who are considered unsuitable for enrollment for other reasons;
  • Exclusion criteria 16 is only applicable to subjects with liver dysfunction 16. Subjects with liver dysfunction can not be included in the group if they have any of the following conditions:

    1. drug-induced liver injury;
    2. Liver transplantation;
    3. Patients with acute liver function injury caused by various reasons within 2 months before screening;
    4. Patients with severe peritoneal effusion or pleural effusion requiring puncture drainage;
    5. Patients with hepatorenal syndrome;
    6. Patients with biliary cirrhosis, biliary obstruction, cholestatic liver disease and other diseases affecting bile excretion;
    7. Patients with severe portal hypertension or who have received previous portosystemic shunt, including transjugular intrahepatic portosystemic shunt;
    8. Patients in the state of liver failure at present, or patients with cirrhosis complicated with obvious hepatic encephalopathy, liver cancer, rupture and bleeding of esophageal and gastric varices and other complications that researchers think are inappropriate;
  • Exclusion criteria 17 is only applicable to healthy subjects. 17. surface antigen (HBsAg) positive or positive.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Anlotinib Hydrochloride Capsules

    Anlotinib hydrochloride capsules, 12mg, 1 time in total

    Drug: Anlotinib Hydrochloride Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Maximum plasma drug concentration

    Time frame: predose, 1,2,4,8,11,24,48,96,144,192,240,336 hours after administration

  2. Area under curve (0-t)

    Area under the plasma concentration-time curve from time 0 to last time of quantifiable concentration

    Time frame: predose, 1,2,4,8,11,24,48,96,144,192,240,336 hours after administration

  3. Area under curve (0-∞)

    Area under the plasma concentration-time curve from time 0 and extrapolated to infinite time

    Time frame: predose, 1,2,4,8,11,24,48,96,144,192,240,336 hours after administration

Secondary outcomes

  1. Time to reach maximum concentration (TMAX)

    Time to reach maximum concentration (TMAX)

    Time frame: predose, 1,2,4,8,11,24,48,96,144,192,240,336,hours after administration

  2. Elimination half life (t1/2)

    Elimination half life (t1/2)

    Time frame: predose, 1,2,4,8,11,24,48,96,144,192,240,336,hours after administration

  3. Apparent clearance (CL/F)

    Apparent clearance (CL/F)

    Time frame: predose, 1,2,4,8,11,24,48,96,144,192,240,336,hours after administration

  4. Apparent distribution volume (Vd/F)

    Apparent distribution volume (Vd/F)

    Time frame: predose, 1,2,4,8,11,24,48,96,144,192,240,336,hours after administration

  5. Adverse event rate

    Incidence and severity of adverse events and serious adverse events, and abnormal laboratory examination indicators

    Time frame: From the first administration to 15 days after the administration

07

Study locations

2 sites
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 40010, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2022; primary completion for Jun 2023, 8 months later.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 8 months is below that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2022
First posted
Sep 29, 2022
StartEst.
Oct 2022
Primary completionEst.
Jun 2023
CompletionEst.
Jul 2023
Last update
Sep 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05559242
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Oct 2022 (estimated)
Primary completion
Jun 2023 (estimated)
Completion
Jul 2023 (estimated)
Last update
Sep 29, 2022

Study contacts

Hong Ren, Master of Medicine
Contact
renhong0531@vip.sina.com.cn
+86 13983888786
Nong Yang, Master of Medicine
Contact
yangnongpi@163.com
+86 13055193557

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Catequentinib hydrochloride

Start the discussion